ALS News Today13h
Utreloxastat fails to slow ALS disease progression in Phase 2 trial
The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...
BioSpace7d
PTC Scraps ALS Asset Utreloxastat After Mid-Stage Fail, Analysts Look to PKU Opportunity
Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...
FierceBiotech7d
PTC axes utreloxastat program after phase 2 ALS failure
But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...
BioSpace2d
Novartis Pays Up to $2.9B in Huntington’s Deal With PTC
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease progression on the composite ...
PTC's utreloxastat fails Phase 2 clinical study for ALS
PTC Therapeutics (NASDAQ:PTCT) said a Phase 2 placebo-controlled study of its ALS drug candidate utreloxastat failed to meet ...
Pharmabiz6d
PTC Therapeutics’ phase 2 CardinALS study of utreloxastat in ALS patients fails to meet primary endpoint
PTC Therapeutics’ phase 2 CardinALS study of utreloxastat in ALS patients fails to meet primary endpoint: Warren, New Jersey Thursday, November 28, 2024, 15:00 Hrs [IST] PTC The ...
PTC Therapeutics, Inc.: PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J., Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced ...